Evidence of Priority to Provisional Application and that Prior Art Was Not Work of Another Defeated Obviousness Challenge in IPR

Apr 6, 2017

Reading Time : 2 min

Every claim in the ’703 Patent requires treatment with the composition for at least two weeks. The ’703 Patent’s corresponding provisional application described a treatment regimen with fampridine that included a two-week upward titration to reach a certain dosage followed by 12 weeks of stable treatment at that dosage. Certain of the claims also require an average steady state plasma concentration (“CavSS”) of the drug within a certain range. The provisional application reported the CavSS levels for treatment using a 10 mg dosage of the drug.

Petitioner argued that disclosure of a 12-week treatment does not specifically teach treatment for two weeks and that there would always be two different concentrations used during the two-week titration period disclosed in the provisional application. Petitioner also argued that the provisional application failed to teach the entire claimed CavSS range. In response, Acorda’s experts explained that there would be no change in dosage during the two-week titration period that corresponded to stable treatment using the lowest dose (10 mg). Moreover, one of skill would consider the standard deviation of reported CavSS values and would understand that the application discloses CavSS values across the entire claimed range. Acorda also introduced declarations from inventors and noninventors indicating that the cited portions of S-1 were the inventors’ own work.

The Board credited Acorda’s experts’ testimony related to the lowest-dose treatment and concluded that the provisional application supported the “two-week limitations” of the ’703 Patent claims. The Board also agreed that one of skill would consider the standard deviation and would have understood the provisional application to disclose the claimed CavSS range. Accordingly, the Board concluded that all claims of the ’703 Patent were entitled to the priority date of the provisional application and that the S-1 reference was therefore not 102(b) prior art to any claim in the IPR.

The Board next considered whether the S-1 reference was the work of others. The Board concluded that Petitioner met its initial burden by presenting S-1 as prior art that, on its face, lists authors that differ from the inventors. However, Acorda responded with declarations indicating that the inventors were the sole source of the cited portions of S-1, satisfying its burden of production to refute Petitioner’s argument. Petitioner’s reply did not persuade the Board that S-1 was not solely attributable to the named inventors. Thus, the Board held that S-1 was not “work by others” and could not qualify as prior art under 102(a). S-1 was therefore not prior art to any claim in the IPR. Because all potential obviousness grounds included S-1, the Board held that Petitioner failed to prove the claims of the ’703 Patent unpatentable as obvious.

Finally, the Board noted that the patents challenged in three related IPR proceedings (IPR2015-01853, IPR2015-01857 and IPR2015-01858) included similar claims. The Board applied its analysis to the claims in those proceedings and, in each case, determined that Petitioner failed to meet its burden to prove those claims unpatentable. The Board’s Final Written Decision therefore resolved those related IPRs.

Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc. IPR2015-01850, IPR2015-01853, IPR2015-01857, IPR2015-01858, Paper No. 72 (PTAB Mar. 9, 2017).

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.